Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03904498 · ClinicalTrials.gov registry record · Phase 2
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
A Phase 2 study of Alcohol Use Disorder and Attention Deficit Hyperactivity Disorder, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT03904498 is a Phase 2 study of Alcohol Use Disorder and Attention Deficit Hyperactivity Disorder that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 62 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03904498, a Phase 2 study of Alcohol Use Disorder and Attention Deficit Hyperactivity Disorder, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether the catechol-O-methyltransferase (COMT) inhibitor tolcapone, relative to placebo, affects response to alcohol, decision-making, brain activation associated with alcohol cue reactivity, response inhibition, and selective attention, or alcohol drinking.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tolcapone
Study Locations (1)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2021-08-16 |
| Est. Completion | 2025-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03904498
The ClinicalTrials.gov registry entry for NCT03904498 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (81% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03904498 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT03904498 about?
NCT03904498 is a clinical study titled "COMT Inhibition Among Individuals With Comorbid AUD/ADHD". The purpose of this study is to determine whether the catechol-O-methyltransferase (COMT) inhibitor tolcapone, relative to placebo, affects response to alcohol, decision-making, brain activation associated with alcohol cue reactivity, response inhibition, and selective attention, or alcohol drinking...
What is the current status of trial NCT03904498?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2021-08-16. Estimated completion is 2025-03-01.
What conditions does trial NCT03904498 study?
This clinical trial studies the following conditions: Alcohol Use Disorder, Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT03904498?
The interventions under investigation include: Placebo (DRUG), Tolcapone (DRUG).
Who is sponsoring clinical trial NCT03904498?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03904498 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
RECRUITING · Phase 2
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial
RECRUITING · Phase 2
-
Cannabis' Impact on Alcohol Consumption
RECRUITING · Phase 2
-
Semaglutide Therapy for Alcohol Reduction (STAR)
RECRUITING · Phase 2
-
A Pilot Study of Non-invasive Brain Stimulation to Boost the Efficacy of Psychotherapy in a Community Sample of People Who Drink Alcohol
RECRUITING · Phase 2
Explore more on PlainTrial
Alcohol Use Disorder
All registered trials for this condition
Attention Deficit Hyperactivity Disorder
All registered trials for this condition
Colorado
All trials with a study site in Colorado
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.